Company intelligence / Profile preview

Atabay Kimya

Istanbul, Istanbul, Turkey

Ownership: Private
Employees: ~800
Development stage: Other

Overview

Atabay is a leading Turkish pharmaceutical company with a heavy focus on the backward integration of API manufacturing. They are one of the world's largest producers of paracetamol API and have successfully commercialized several anti-viral treatments. Their recent clinical focus has shifted towards the development of biosimilars and VLP-based vaccines.

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculeBiologicVaccinePeptidesRecombinant protein
Industry: Biotech

Partnerships

TÜBİTAKNobel İlaç

Beyond the preview

Go deeper on Atabay Kimya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atabay Kimya.

Explore the full profile